A brief review of 2 oral JAK inhibitors recently approved for patients with atopic dermatitis.

Dermatology Times® interviews editorial board member Richard Gallo, MD, PhD, who dives into what is currently lacking is rosacea patient care, how the new mechanisms of action of these potential treatments will better address current struggles, and more.

Jashin Wu, MD, FAAD, the founder and course director of the 3rd Annual San Diego Dermatology Symposium, offers highlights of the gamechanging topics on the agenda for this in-person conference set for March 11-13, 2022, in San Diego, California. Watch to see more information about the presentations.

In this week’s Pointers with Dr Portela, the 208SkinDoc has a discussion with Marvin Rapaport MD, about the potential adverse events that may occur when patients overuse topical steroids. Watch the interview, meant for educational purposes only, to see what they had to say.

A panel of experts review the use of topical ruxolitinib in atopic dermatitis, shedding light on safety and efficacy considerations.

Focusing on JAK inhibitors, panelists consider the historical use of these agents in atopic dermatitis and their corresponding mechanisms of action.

In this week’s Pointers with Dr Portela, the 208SkinDoc reacts to Nicki Minaj’s tweets about skin care, diving into whether her advice is true or not, and if a dermatology would recommend her routine.

Experts define stages of atopic dermatitis and share insight on the conventional treatment landscape for mild to moderate and moderate to severe atopic dermatitis.

Expert perspectives on the nature of atopic dermatitis, ranging from diagnosis and pathophysiology to the clinical and social burden it places on patients.

In a follow up interview about the results from the American Academy of Facial Plastic and Reconstructive Surgery annual survey AAFPRS president Corey S. Maas, MD, sits down to talk in depth details about the outcomes.

Drs James Q. Del Rosso and Neal Bhatia explain how to manage patients who fail therapy and provide safety considerations when treating those patients.

In this week’s Pointers with Dr Portela, the 208SkinDoc reacts to an episode of Botched, which was about a patient with basal cell carcinoma (BCC), whose tanning in her younger years led to Mohs surgery.

A recent mouse model study on the efficacy of using imatinib as a treatment for Sturge Weber Syndrome has been published. In this video interview we talk with one of the investigators, Jack L. Arbiser, MD, PhD, on what the results means for future clinical trials.

Experts discuss newly approved oral JAK inhibitors for the treatment of atopic dermatitis.

In this week’s Pointers with Dr Portela, the 208SkinDoc dives into the newest attempt at blue light protecting skin care, providing a full review of the products, its ingredients, and if there is any science behind its claims.

We sit down with the experts to determine what legal and tax factors come into play when deciding on the best corporate structure for a dermatology practice.

A review of topical JAK inhibitor ruxolitinib.

In this week’s Pointers with Dr Portela, the 208SkinDoc highlights a growing issue of lasers made to look like or mimic the technology of already approved lasers but can have dangerous consequences.

James Q. Del Rosso, DO, and Neal Bhatia, MD, provide an overview of JAK inhibitors for the treatment of atopic dermatitis.

Closing out their discussion on the management of plaque psoriasis, panelists share their excitement for future directions in care.